These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 38393178)

  • 1. Complexing Protein-Free Botulinum Neurotoxin A Formulations: Implications of Excipients for Immunogenicity.
    Martin MU; Frevert J; Tay CM
    Toxins (Basel); 2024 Feb; 16(2):. PubMed ID: 38393178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials.
    Gallagher CJ; Bowsher RR; Clancy A; Dover JS; Humphrey S; Liu Y; Prawdzik G
    Toxins (Basel); 2023 Jan; 15(1):. PubMed ID: 36668880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines.
    Humphrey S; Dover JS; Bowsher RR; Clancy A; Liu Y; Prawdzik G; Gallagher CJ
    Aesthet Surg J; 2023 Sep; 43(10):1189-1193. PubMed ID: 37051886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
    Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
    Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity Associated with Botulinum Toxin Treatment.
    Bellows S; Jankovic J
    Toxins (Basel); 2019 Aug; 11(9):. PubMed ID: 31454941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Near-Infrared Transflectance Spectroscopy Discriminates Solutions Containing Two Commercial Formulations of Botulinum Toxin Type A Diluted at Recommended Volumes for Clinical Reconstitution.
    Currà A; Gasbarrone R; Bonifazi G; Serranti S; Fattapposta F; Trompetto C; Marinelli L; Missori P; Lendaro E
    Biosensors (Basel); 2022 Apr; 12(4):. PubMed ID: 35448275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IncobotulinumtoxinA: A Highly Purified and Precisely Manufactured Botulinum Neurotoxin Type A.
    Kerscher M; Wanitphakdeedecha R; Trindade de Almeida A; Maas C; Frevert J
    J Drugs Dermatol; 2019 Jan; 18(1):52-57. PubMed ID: 30681794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins.
    Jimenez-Shahed J
    Neuropsychiatr Dis Treat; 2012; 8():13-25. PubMed ID: 22275842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A.
    Solish N; Carruthers J; Kaufman J; Rubio RG; Gross TM; Gallagher CJ
    Drugs; 2021 Dec; 81(18):2091-2101. PubMed ID: 34787840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic Implications.
    Carr WW; Jain N; Sublett JW
    Adv Ther; 2021 Oct; 38(10):5046-5064. PubMed ID: 34515975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm.
    Park J; Lee MS; Harrison AR
    Clin Ophthalmol; 2011; 5():725-32. PubMed ID: 21691580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders.
    Naumann M; Dressler D; Hallett M; Jankovic J; Schiavo G; Segal KR; Truong D
    Toxicon; 2013 Jun; 67():141-52. PubMed ID: 23178324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions.
    Chancellor MB; Elovic E; Esquenazi A; Naumann M; Segal KR; Schiavo G; Smith CP; Ward AB
    Toxicon; 2013 Jun; 67():129-40. PubMed ID: 23415704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer.
    Chen JJ; Dashtipour K
    Pharmacotherapy; 2013 Mar; 33(3):304-18. PubMed ID: 23400888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome.
    Esquenazi A; Albanese A; Chancellor MB; Elovic E; Segal KR; Simpson DM; Smith CP; Ward AB
    Toxicon; 2013 Jun; 67():115-28. PubMed ID: 23220492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical differences between botulinum neurotoxin type A and B.
    Bentivoglio AR; Del Grande A; Petracca M; Ialongo T; Ricciardi L
    Toxicon; 2015 Dec; 107(Pt A):77-84. PubMed ID: 26260691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of botulinum toxin immunogenicity.
    Benecke R
    BioDrugs; 2012 Apr; 26(2):e1-9. PubMed ID: 22385408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity induced by botulinum toxin injections for limb spasticity: A systematic review.
    Mathevon L; Declemy A; Laffont I; Perennou D
    Ann Phys Rehabil Med; 2019 Jul; 62(4):241-251. PubMed ID: 30980953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of human serum albumin and neurotoxin associated proteins in the formulation of BoNT/A products.
    Kutschenko A; Bigalke H; Wegner F; Wohlfarth K
    Toxicon; 2019 Oct; 168():158-163. PubMed ID: 31323228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Narrative Literature Review of the Established Safety of Human Serum Albumin Use as a Stabilizer in Aesthetic Botulinum Toxin Formulations Compared to Alternatives.
    Sattler S; Gollomp S; Curry A
    Toxins (Basel); 2023 Oct; 15(10):. PubMed ID: 37888650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.